Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FSHR | P23945 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17518970 | 0.88 | ATR (0.53) | ATRMETAP1AAK1CYP17A1MAPKAPK2 | |
| SCHEMBL30737936 | 0.85 | AURKA (0.56) | — | |
| SCHEMBL2300386 | 0.84 | ATR (0.47) | ATRMETAP1AAK1CYP17A1MAPKAPK2 | |
| SCHEMBL5203135 | 0.84 | NPC1 (0.47) | ATRAAK1CYP17A1MAPKAPK2 | |
| SCHEMBL17518971 | 0.84 | ATR (0.47) | ATRMETAP1AAK1CYP17A1MAPKAPK2 | |
| SCHEMBL29768000 | 0.83 | ATR (0.46) | ATRMETAP1AAK1CYP17A1MAPKAPK2 | |
| SCHEMBL4648083 | 0.83 | ATR (0.52) | ATRGSK3BDYRK1AMETAP1AAK1 | |
| SCHEMBL27267125 | 0.82 | ATR (0.45) | ATRGSK3BDYRK1AMETAP1CYP17A1 | |
| SCHEMBL15263437 | 0.81 | ATR (0.44) | ATRAAK1CYP17A1MAPKAPK2 | |
| SCHEMBL15508380 | 0.81 | SYK (0.47) | ATRAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087629-B2 | Useful activity against Gram-positive pathogens and, in particular, against various strains exhibiting resistance to vancomycin and against E. faecium strains resistant to both aminoglycosides and clinically used beta-lactams | ASTRAZENECA AB (SE) | 2006-08-08 | — | — | US | disclosed |